Hepatocellular Carcinoma (HCC) is the most common type of liver cancer. It starts in liver cells called hepatocytes. HCC happens most often in people with chronic liver conditions such as cirrhosis caused by hepatitis B or hepatitis C infection. The 5-year survival rate is about 20% for all stages. Immunotherapy has become a standard treatment for advanced HCC. The combination of an anti-PD-L1 antibody and an anti-VEGF antibody is a leading first-line therapy, though other combination therapies are also being used. Here, at Vera Bio, we’re developing an alternative to immunotherapy - in particular, for patients who cannot tolerate immunotherapy.